Stem-cell transplantation in myocardial infarction: a status report.
Myocardial infarction is the leading cause of congestive heart failure and death in the industrialized world. Current therapy is limited in preventing the progression of ventricular remodeling and congestive heart failure. Recent interest has focused on stem cells, which are undifferentiated and pluripotent cells that can proliferate, potentially self-renew, and differentiate into cardiomyocytes. Myocardial regeneration with stem-cell transplantation is a possible treatment option to reverse the deleterious hemodynamic and neurohormonal effects that occur after myocardial infarction and can lead to congestive heart failure. Various preclinical animal studies show the potential to regenerate myocardium and improve perfusion to the infarct area to improve cardiac function but also suggest that stem cells may have proarrhythmic effects. Early phase I clinical studies indicate that stem-cell transplantation is feasible and may have beneficial effects on ventricular remodeling after myocardial infarction. Future randomized clinical trials will establish the magnitude of the benefit and the effects on arrhythmias after stem-cell therapy.
Lee
Michael S
MS
St. Luke's-Roosevelt Hospital Center, College of Physicians and Surgeons, New York, New York 10025, USA.
Makkar
Raj R
RR
D000818:Animals; D017321:Clinical Trials, Phase I as Topic; D018450:Disease Progression; D006333:Heart Failure / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D023421:Models, Animal; D009203:Myocardial Infarction / Q000503:physiopathology / Q000628:therapy*; D033581:Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods; D020257:Ventricular Remodeling / Q000502:physiology